The company said, “Xeris also announced preliminary second quarter 2024 total revenue to exceed $47.0 million, representing more than 23% growth over last year, and reaffirms year-end 2024 cash guidance of $55 million to $75 million. The Company will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Pharmaceuticals Shareholders Back Key Proposals and Directors
- Xeris presents data on SONICS study on effects of levoketoconazole on CS
- Xeris announces XeriSol data formulated once-weekly SC levothyroxine
- Xeris Biopharma price target lowered to $3 from $4 at Piper Sandler
- Xeris Biopharma reports Q1 EPS (14c), consensus (12c)